Danaher shares trade around $194.78 after a weak earnings update and the planned 2026 CEO transition to Julie Sawyer Montgomery, with a Discounted Cash Flow analysis pointing to an intrinsic value of about $230 per share, implying a roughly 15.2% discount. The DCF model starts with trailing twelve-month free cash flow of approximately $5.3 billion and assumes continued growth from that base. However, Danaher’s price-to-earnings ratio of about 34.3 times sits above a tailored fair P/E of roughly 28.9 times, signaling overvaluation on earnings even though it is below the Life Sciences industry average of around 37.6 times and the peer group average of about 79.6 times. Broader checks score 3 out of 6, reflecting a mixed picture as investors weigh whether execution under the new CEO and future cash flow delivery can justify the current earnings multiple or confirm a value trap.
Danaher CorporationDCF suggests 15% upside but P/E flags overvaluation; mixed signals on valuation and CEO transition.
